New COVID-19 Codes To Be Implemented Soon

Sue Bowman, MJ, RHIA, CCS, FAHIMA

By Sue Bowman, MJ, RHIA, CCS, FAHIMA

In response to the COVID-19 public health emergency, the Centers for Disease Control and Prevention’s National Center for Health Statistics (CDC/NCHS) and the Centers for Medicare and Medicaid Services (CMS) are implementing six new ICD-10-CM and 21 new ICD-10-PCS codes, effective January 1, 2021.

The new ICD-10-CM diagnosis codes are:

ICD-10-CM

Code

Description
J12.82Pneumonia due to coronavirus disease 2019
M35.81Multisystem inflammatory syndrome
M35.89Other specified systemic involvement of connective tissue
Z11.52Encounter for screening for COVID-19
Z20.822Contact with and (suspected) exposure to COVID-19
Z86.16Personal history of COVID-19

New ICD-10-CM code M35.81 describes multisystem inflammatory syndrome (MIS), a hyperinflammatory syndrome associated with past or present COVID-19 (SARS-CoV-2 infection). It has been predominantly described in children with less frequent case reports in adults. The current US CDC case definition for MIS in children includes fever, laboratory markers of inflammation, severe illness requiring hospitalization with at least two organ systems involved and laboratory evidence of SARS-CoV-2 infection or a history of known exposure to a suspected or confirmed COVID-19 case within four weeks prior to symptom onset.

The ICD-10-CM Addenda and other code files are available on the CDC/NCHS ICD-10-CM web page: https://www.cdc.gov/nchs/icd/icd10cm.htm. The updated ICD-10-CM Official Guidelines for Coding and Reporting are expected to be posted on this page soon.

The new ICD-10-PCS procedure codes going into effect January 1 describe the introduction or infusion of therapeutics, including monoclonal antibodies, for COVID-19 treatment and vaccines. CMS stated that for hospitalized patients, Medicare pays for the COVID-19 vaccines and their administration separately from the Diagnosis-Related Group rate. As such, Medicare expects that the appropriate CPT codes (see the discussion below concerning new CPT codes for COVID-19 vaccines) will be used when a Medicare beneficiary is administered a vaccine while a hospital inpatient. For details on billing Medicare for the COVID-19 vaccine appropriately, please see the CMS website: https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration.

The new ICD-10-PCS procedure codes are:

ICD-10-PCS

Code

Description
XW013H6Introduction of other new technology monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6
XW013K6Introduction of leronlimab monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6
XW013S6Introduction of COVID-19 vaccine dose 1 into subcutaneous tissue, percutaneous approach, new technology group 6
XW013T6Introduction of COVID-19 vaccine dose 2 into subcutaneous tissue, percutaneous approach, new technology group 6
XW013U6Introduction of COVID-19 vaccine into subcutaneous tissue, percutaneous approach, new technology group 6
XW023S6Introduction of COVID-19 vaccine dose 1 into muscle, percutaneous approach, new technology group 6
XW023T6Introduction of COVID-19 vaccine dose 2 into muscle, percutaneous approach, new

technology group 6

XW023U6Introduction of COVID-19 vaccine into muscle, percutaneous approach, new technology group 6
XW033E6Introduction of etesevimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033F6Introduction of bamlanivimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033G6Introduction of REGN-COV2 monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033H6Introduction of other new technology monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
XW033L6Introduction of CD24Fc immunomodulator into peripheral vein, percutaneous approach, new technology group 6
XW043E6Introduction of etesevimab monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043F6Introduction of bamlanivimab monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043G6Introduction of REGN-COV2 monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043H6Introduction of other new technology monoclonal antibody into central vein, percutaneous approach, new technology group 6
XW043L6Introduction of CD24Fc immunomodulator into central vein, percutaneous approach, new technology group 6
XW0DXM6Introduction of baricitinib into mouth and pharynx, external approach, new technology group 6
XW0G7M6Introduction of baricitinib into upper GI, via natural or artificial opening, new technology group 6
XW0H7M6Introduction of baricitinib into lower GI, via natural or artificial opening, new technology group 6

The ICD-10-PCS Code Tables, Index, and Addenda for the new ICD-10-PCS codes are available on the CMS 2021 ICD-10-PCS web page: https://www.cms.gov/medicare/icd-10/2021-icd-10-pcs.

In the CPT code set, the American Medical Association (AMA) has created a new vaccine coding structure for COVID-19 vaccine candidates. This new structure differs from that of other CPT vaccine codes. A Special Edition of the AMA’s CPT Assistant indicated that this structural change is due in part to the rapid development of COVID-19 vaccines, a request to track the administration of each individual vaccine, and the need for a long-term solution to accommodate additional codes as new vaccines become available. A request to track both the specific vaccine and the dose received resulted in a series of alphanumeric COVID-19 vaccine administration codes. These administration codes include vaccine risk and benefit counseling, when performed.

The new CPT codes for COVID-19 vaccines, which will be effective upon receiving approval or Emergency Use Authorization from the US Food and Drug Administration, are:

CPT CodeDescription
91300Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
91301Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
0001AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
0002AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
0011AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
0012AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose

Each COVID-19 vaccine administration code (0001A, 0002A, 0011A, 0012A) is specific to each individual vaccine product code (91300, 91301). The appropriate administration code is chosen based on the type of vaccine and which dose in the schedule (first or second dose) the patient receives.

Appendix Q provides a table that links the individual COVID-19 vaccine product codes to their associated immunization administration codes, manufacturer name, vaccine name(s), National Drug Code (NDC) Labeler Product ID, and interval between doses.

Detailed information about the COVID-19 CPT vaccine and immunization codes can be found on the AMA website: https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes.

Sue Bowman ([email protected]) is senior director, coding policy and compliance at AHIMA.

Leave a commentSyndicated from https://journal.ahima.org/new-covid-19-codes-to-be-implemented-soon/

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.